Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Authors
Horwitz, SO'Connor, O
Pro, B
Illidge, Timothy M
Fanale, M
Advani, R
Bartlett, N
Christensen, J
Morschhauser, F
Domingo-Domenech, E
Rossi, G
Kim, W
Feldman, T
Lennard, A
Belada, D
Illes, A
Tobinai, K
Tsukasaki, K
Yeh, S
Shustov, A
Huttmann, A
Savage, K
Yuen, S
Iyer, S
Zinzani, P
Hua, Z
Little, M
Rao, S
Woolery, J
Manley, T
Trumper, L
Aboulafia, D
Alpdogan, O
Ando, K
Arcaini, L
Baldini, L
Bellam, N
Bartlett, N
Yehuda, DB
Benedetti, F
Borchman, P
Bordessoule, D
Brice, P
Briones, J
Caballero, D
Carella, A
Chang, H
Cheong, J
Cho, S
Choi, I
Choquet, S
Colita, A
Congui, A
D'amore, F
Dang, N
Davison, K
De, Guibert S
Brown, P
Delwail, V
Demeter, J
di Raimondo, F
Do, Y
Domingo, E
Douvas, M
Dreyling, M
Ernst, T
Fay, K
Ferrero, S
Flinn, I
Forero-Torres, A
Fox, C
Friedberg, J
Fukuhara, N
Garcia-Marco, J
Cruz, J
Codina, J
Gressin, R
Grigg, A
Gurion, R
Haioun, C
Hajek, R
Hanel, M
Hatake, K
Hensen, R
Horowitz, N
Huttmann, A
Ishizawa, K
Islas-Ohlmayer, M
Jacobsen, E
Janakiram, M
Jurczak, W
Kaminski, M
Kato, K
Kirgner, I
Kuo, C
Lazaroiu, M
Le, Du, K
Lee, J
Legouill, S
Larosee, P
Levi, I
Link, B
Maisonneuve, H
Maruyama, D
Mayer, J
McCarty, J
Mckay, P
Minami, Y
Mocikova, H
Morra, E
Munoz, J
Nagai, H
O'Connor, O
Opat, S
Pettengell, R
Pezzutto, A
Pfreundschuh, M
Pluta, A
Porcu, P
Quach, H
Rambaldi, A
Renwick, W
Reyes, R
Izquierdo, A
Ruan, J
Rusconi, C
Salles, G
Santoro, A
Sarriera, J
Savage, K
Shibayama, H
Suh, C
Sureda, A
Tanimoto, M
Taniwaki, M
Tilly, H
Trneny, M
Trumper, L
Tsukamoto, N
Vitolo, U
Walewski, J
Weidmann, E
Wilhelm, M
Witzens-Harig, M
Yacoub, A
Yamamoto, K
Yoon, S
Yun, H
Zain, J
Zinzan, P
Affiliation
Memorial Sloan Kettering Cancer Center, New YorkIssue Date
2019
Metadata
Show full item recordCitation
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-40.Journal
LancetDOI
10.1016/S0140-6736(18)32984-2PubMed ID
30522922Additional Links
https://dx.doi.org/10.1016/S0140-6736(18)32984-2Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/S0140-6736(18)32984-2
Scopus Count
Collections
Related articles
- Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
- Authors: Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR
- Issue date: 2014 Oct 1
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
- Authors: Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T
- Issue date: 2022 Mar
- Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.
- Authors: Herrera AF, Zain J, Savage KJ, Feldman T, Brammer JE, Chen L, Puverel S, Popplewell L, Budde LE, Mei M, Hosing C, Nair R, Leslie L, Daniels S, Peters L, Forman S, Rosen S, Kwak L, Iyer SP
- Issue date: 2024 Sep
- Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
- Authors: Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P
- Issue date: 2017 Dec
- Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
- Authors: Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J
- Issue date: 2021 Jun